Development of Processes for Recombinant L-Asparaginase II Production by Escherichia coli Bl21 (De3): From Shaker to Bioreactors

Since 1961, L-asparaginase has been used to treat patients with acute lymphocytic leukemia. It rapidly depletes the plasma asparagine and deprives the blood cells of this circulating amino acid, essential for the metabolic cycles of cells. In the search for viable alternatives to produce L-asparagin...

Descripción completa

Detalles Bibliográficos
Autores principales: Barros, Thaís, Brumano, Larissa, Freitas, Marcela, Pessoa, Adalberto, Parachin, Nádia, Magalhães, Pérola O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823503/
https://www.ncbi.nlm.nih.gov/pubmed/33374100
http://dx.doi.org/10.3390/pharmaceutics13010014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823503/
https://www.ncbi.nlm.nih.gov/pubmed/33374100
http://dx.doi.org/10.3390/pharmaceutics13010014

Ejemplares similares